Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study

OBJECTIVE: Second-line treatment of endometrial cancer is an unmet medical need. We conducted a phase I study evaluating lurbinectedin and doxorubicin intravenously every 3 weeks in patients with solid tumors. The aim of this study was to characterise the efficacy and safety of lurbinectedin and dox...

Descripción completa

Detalles Bibliográficos
Autores principales: Kristeleit, Rebecca, Moreno, Victor, Boni, Valentina, Guerra, Eva M, Kahatt, Carmen, Romero, Ignacio, Calvo, Emiliano, Basté, Neus, López-Vilariño, José A, Siguero, Mariano, Alfaro, Vicente, Zeaiter, Ali, Forster, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573419/
https://www.ncbi.nlm.nih.gov/pubmed/34610971
http://dx.doi.org/10.1136/ijgc-2021-002881

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573419/
https://www.ncbi.nlm.nih.gov/pubmed/34610971
http://dx.doi.org/10.1136/ijgc-2021-002881

Ejemplares similares